NDC 43386-071 Gavilyte-h And Bisacodyl

Polyethylene Glycol 3350,Sodium Chloride,Sodium Bicarbonate,Potassium Chloride And - View Dosage, Usage, Ingredients, Routes, UNII

Product Information

NDC Product Code:
43386-071
Proprietary Name:
Gavilyte-h And Bisacodyl
Non-Proprietary Name: [1]
Polyethylene Glycol 3350, Sodium Chloride, Sodium Bicarbonate, Potassium Chloride And Bisacodyl Delayed-release Tablet
NDC Directory Status:
Human Prescription Drug
Product Type: [3]
ACTIVE PRODUCT INCLUDED in the NDC Directory
Dosage Form:
Kit - A packaged collection of related material.
Administration Route(s): [4]
  • Oral - Administration to or by way of the mouth.
  • Labeler Code:
    43386
    FDA Application Number: [6]
    ANDA202217
    Marketing Category: [8]
    ANDA - A product marketed under an approved Abbreviated New Drug Application.
    Start Marketing Date: [9]
    04-21-2015
    Listing Expiration Date: [11]
    12-31-2024
    Exclude Flag: [12]
    N
    Code Navigator:

    Product Characteristics

    Color(s):
    PINK (C48328)
    Shape:
    ROUND (C48348)
    Size(s):
    9 MM
    Imprint(s):
    N1
    Score:
    1

    Code Structure Chart

    Product Details

    What is NDC 43386-071?

    The NDC code 43386-071 is assigned by the FDA to the product Gavilyte-h And Bisacodyl which is a human prescription drug product labeled by Lupin Pharmaceuticals, Inc.. The generic name of Gavilyte-h And Bisacodyl is polyethylene glycol 3350, sodium chloride, sodium bicarbonate, potassium chloride and bisacodyl delayed-release tablet. The product's dosage form is kit and is administered via oral form. The product is distributed in a single package with assigned NDC code 43386-071-83 1 kit in 1 kit * 1 tablet, delayed release in 1 blister pack (43386-010-61) * 2 l in 1 bottle (43386-070-17). This page includes all the important details about this product, including active and inactive ingredients, pharmagologic classes, product uses and characteristics, UNII information and RxNorm crosswalk.

    What are the uses for Gavilyte-h And Bisacodyl?

    GaviLyte - H and bisacodyl delayed-release tablet, USP is indicated for cleansing of the colon as a preparation for colonoscopy in adults.

    Which are Gavilyte-h And Bisacodyl UNII Codes?

    The UNII codes for the active ingredients in this product are:

    Which are Gavilyte-h And Bisacodyl Inactive Ingredients UNII Codes?

    The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:

    What is the NDC to RxNorm Crosswalk for Gavilyte-h And Bisacodyl?

    RxNorm is a normalized naming system for generic and branded drugs that assigns unique concept identifier(s) known as RxCUIs to NDC products.The NDC to RxNorm Crosswalk for this produdct indicates multiple concept unique identifiers (RXCUIs) are associated with this product:
    • RxCUI: 1000479 - {1 (bisacodyl 5 MG Delayed Release Oral Tablet) / 1 (2000 ML) (polyethylene glycol 3350 210000 MG / potassium chloride 740 MG / sodium bicarbonate 2860 MG / sodium chloride 5600 MG Powder for Oral Solution) } Pack
    • RxCUI: 1000479 - 1 (PEG-3350 210 GM / potassium chloride 0.74 GM / sodium bicarbonate 2.86 GM / sodium chloride 5.6 GM Powder for Oral Solution) / 1 (bisacodyl 5 MG Delayed Release Oral Tablet) Pack
    • RxCUI: 1000479 - PEG-3350 210 GM / potassium chloride 0.740 GM / sodium bicarbonate 2.86 GM / sodium chloride 5.6 GM Powder for 2 L Oral Solution / 1 x bisacodyl 5 MG Delayed Release Oral Tablet
    • RxCUI: 1718983 - polyethylene glycol-3350 210 GM / potassium chloride 0.74 GM / sodium bicarbonate 2.86 GM / sodium chloride 5.6 GM Powder for Oral Solution
    • RxCUI: 1718983 - polyethylene glycol 3350 210000 MG / potassium chloride 740 MG / sodium bicarbonate 2860 MG / sodium chloride 5600 MG Powder for Oral Solution

    * Please review the disclaimer below.

    Product Footnotes

    [1] What is the Non-Proprietary Name? - The non-proprietary name is sometimes called the generic name. The generic name usually includes the active ingredient(s) of the product.

    [3] What kind of product is this? - Indicates the type of product, such as Human Prescription Drug or Human Over the Counter Drug. This data element matches the “Document Type” field of the Structured Product Listing.

    [4] What are the Administration Routes? - The translation of the route code submitted by the firm, indicating route of administration.

    [5] What is the Labeler Name? - Name of Company corresponding to the labeler code segment of the Product NDC.

    [6] What is the FDA Application Number? - This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.

    [8] What is the Marketing Category? - Product types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

    [9] What is the Start Marketing Date? - This is the date that the labeler indicates was the start of its marketing of the drug product.

    [11] What is the Listing Expiration Date? - This is the date when the listing record will expire if not updated or certified by the product labeler.

    [12] What is the NDC Exclude Flag? - This field indicates whether the product has been removed/excluded from the NDC Directory for failure to respond to FDA"s requests for correction to deficient or non-compliant submissions ("Y"), or because the listing certification is expired ("E"), or because the listing data was inactivated by FDA ("I"). Values = "Y", "N", "E", or "I".